Meeting
2020 ASCO Virtual Scientific Program
Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy (P) after FDA approval.
Authors
Tamara Snow
Flatiron Health, New York, NY
Tamara Snow , Akshay Swaminathan , Jeremy Snider , Alexa Betzig Schrock , Gerald Li , Brian Michael Alexander , Gaurav Singal , Emily Castellanos , Margaret Elizabeth McCusker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3060)
DOI
10.1200/JCO.2020.38.15_suppl.3060
Abstract #
3060
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
First Author: Cody Eslinger
Poster
2023 ASCO Annual Meeting
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.
First Author: Amit Mahipal
Poster
2018 ASCO Annual Meeting
Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors.
First Author: Mohamed E. Salem
Poster
2016 ASCO Annual Meeting
KEYNOTE-164: phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.
First Author: Dung T. Le